SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today new, five-year efficacy, safety and durability data from the Phase ...
Add Yahoo as a preferred source to see more of our stories on Google. Dr Dao Nguyen examines a vial of lutein formulation developed for potential use in eyedrop treatments. (CREDIT: Will Wright, RMIT ...
Roche was approved by the European Commission for Susvimo (ranibizumab 100 mg/mL solution for injection) for the treatment of neovascular age-related macular degeneration (nAMD). Susvimo is the first ...
Roche Holding AG ( RHHBY) said the European Commission has approved Susvimo (ranibizumab 100 mg/mL) for the treatment of neovascular age-related macular degeneration in adults.
Australian scientists have successfully used an innovative gene therapy technique in the lab to combat a key cause of vision loss in "wet" age-related macular degeneration and diabetic eye disease.
Many surgeons admit that medical robots can now operate with greater precision than human specialists. However, the complex preparation required for robotic surgery still takes far too long. But a new ...
Researchers at Science Tokyo developed an mRNA vaccine that suppressed abnormal retinal blood vessel growth in mouse models. The vaccine can be administered intramuscularly and showed effectiveness ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results